Abstract: Raf-1 Kinase Inhibitory Protein (RKIP) belongs to a new class modulators of signalling cascades involved in maintaining of biological balance in many living organisms.
INTRODUCTION
Thyroid carcinoma is the most common malignancy of the endocrine system and it includes follicular, papillary and undifferentiated thyroid tumors. Patients suffering from differentiated thyroid carcinomas such as papillary (PTC) and follicular (FTC) are generally well treatable and usually curable. Papillary thyroid carcinoma may occur at all ages, often with an optimistic prognosis and survival rates of more than 90%. Follicular thyroid carcinoma predicts more aggressive behaviour with recurrences or/and distant metastases to liver, lung and bones. Undifferentiated thyroid tumors (UTC), also termed, anaplastic, are much less common, metastasize early, and have a much poorer prognosis with a 5 years survival rates lower than 5% [1] [2] [3] [4] . The majority of patients die due to metastatic disease. The list of tumor markers with prognostic or predictive values has been considerably increasing [5] , however, only few of them correlate well with the presence of metastases in thyroid carcinoma [6] [7] [8] [9] [10] [11] .
RKIP was shown to be a critical down-regulator of MAP kinase signalling (Raf-MEK-ERK) and alteration of this pathway is involved in about 30% of all cancers [12] . Additionally to Raf-1 inhibition, RKIP is able to block the activation of NF-B and GPCR kinase [13, 14] . Loss or reduction of RKIP has previously been shown to be associated with *Address correspondence to this author at the AG Experimentelle & Chirurgische Onkologie, Universitätsklinik und Poliklinik für Allgemein-, Viszeral-und Gefäßchirurgie, Magdeburger Str. 18, D-06097 Halle/S., Germany; Tel: +49-345-557 1366; Fax: +49-345-557-1232; E-mail: hoang-vu@medizin.uni-halle.de metastasis of melanoma, prostate, colorectal, breast and ovarian cancers [15] [16] [17] [18] [19] [20] . In this study we investigated the expression of RKIP in thyroid carcinomas.
MATERIALS AND METHODOLOGY
Thyroid tissues. A total of 54 primary thyroid tissues, including 23 follicular thyroid carcinomas (FTCs), 18 papillary thyroid carcinomas (PTCs) and 13 undifferentiated thyroid carcinomas (UTCs), were collected from patients operated on at the Department of Surgery, University of Halle. Tissues selected for RKIP analysis were primary tumors with complete clinicopathological data and TNM status ( Table 1) . Tumor tissues were staged according to the tumornode-metastasis (TNM) staging classification (UICC-AJCC 1997). This study was approved by the ethical committee of the Martin Luther University, Faculty of Medicine, and all patients gave written consent.
Protein extraction. Resected thyroid tissues were immediately frozen in liquid nitrogen, homogenized and incubated in lysis buffer prepared by mixing 1.5 ml 5M NaCl, 1 ml 1M Tris/HCl pH 7.5, 50 l 0.5M EDTA pH 8.0, 50 l 0.5M pH 7.5 and 250 l Trition X-100 stock solutions, diluted with Aquabidest to 50ml. Protease inhibitors were added to obtain following end concentrations: 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 g/ml apoprotenin, and 1 g/ml leupeptin. Protein lysates were incubated on ice for 15 min., followed by centrifugation twice at 16000 x g for 45 min. at 4°C. The supernatant was saved for protein analysis.
Western blot analysis. Protein extracts were separated on 12% polyacrylamide gels and blotted on PVDF membranes Statistical analysis. Independent sample t and KruskalWallis tests were used to compare the association between RKIP expression level and clinicopathological factors. All of the statistical tests were two-sided. Box plots were made employing SPSS software. The p values below 0.05 were considered to be statistically significant.
RESULTS

Expression of RKIP in thyroid carcinoma tissues.
We analyzed the expression of RKIP in 54 thyroid carcinoma patients employing western blotting (Fig. 1) . According to our criteria, RKIP was found to be very weak and reduced (signal intensity below 70%) in 36 of 54 cases analyzed (66.7%). We found no significant age and gender differences among patients with normal and reduced RKIP expression. Also no significant associations were found between downregulation of RKIP and histological differentiation or tumor stage. Although the above-mentioned differences were not significant, patients with low or reduced RKIP expression bore more T4 tumors at the time of surgery than did patients without RKIP down-regulation (22 of 32 cases, 68.8%). Out of 35 patients with decreased RKIP expression; 22 of them bore T4 tumors (62.9%). Out of 19 patients with normal RKIP level, 10 suffered from T4 tumors (52.6%, Table 2 ).
RKIP expression is significantly reduced in metastatic thyroid carcinoma. As shown in Table 1 , patients who developed lymph node or distant metastases, revealed reduced RKIP expression in 30 of 39 N1 cases (76.9%) and in 17 of 20 M1 cases (85%). Analysis of all RKIP signal intensities in various groups of patients with lymph node and/or distant metastases was evaluated employing box plot. We found that RKIP expression was highly reduced in all cases with either lymph node or distant metastases when compared to N0 or M0 cases, respectively (Fig. 2a, p<0.05; Fig. 2b, p<0.05) . Comparison of lymph node and distant metastases negative (N0M0) patients with N1M0, N0M1 or N1M1 patients, also revealed significantly decreased RKIP expression in each comparison group (Fig. 2c, p<0.05) . Comparisons within the metastatic groups (N1M0, N0M1, and N1M1) demonstrated no significant differences, however, the most reduced RKIP expression was observed in the metastatic group N1M1.
DISCUSSION
This is the first report demonstrating the association of RKIP with metastases of thyroid carcinoma. We show in this study that RKIP expression is significantly reduced in patients suffering from lymph node and/or distant metastases. RKIP has been identified as a growth suppressive gene and its expression was diminished or lost in metastases of melanoma, prostate, colorectal, breast and ovarian cancers [15] [16] [17] [18] [19] [20] . Reduction of RKIP was also reported for insulinomas and hepatocellular carcinoma tissues [21, 22] . In patients with gastric adenocarcinoma, decreased expression of RKIP correlated positively with 5-year survival rates [23] .
We demonstrated RKIP as a crucial inhibitor of MAP kinase pathway involved in thyroid pathogenesis. Previous studies reported several other MAP kinase effectors essential for progression of thyroid carcinoma, especially PTC. The most important are the tyrosine receptor kinase RET and the intracellular signalling effectors RAS and BRAF. It was shown that mutations in genes encoding these factors, lead to constitutive activation of MAP kinase signalling [24] [25] [26] .
The specific actions involved in RKIP regulation of Raf signalling are not entirely clear. It has been shown that overexpression of RKIP can inhibit MEK-Raf-1 or MEK-B-Raf interaction [27] . By using siRNA, it has been demonstrated that Raf-1 activation was blocked by preventing phosphorylation at serine 338 and tyrosine 341. Interestingly, activation of B-Raf was not regulated by RKIP [28] . Depletion of RKIP in embryonic fibroblasts from double knockout Raf-1 -/-mouse caused an increase of B-Raf mediated MEK activity. These results suggest that RKIP can regulate B-Raf independently of Raf-1 [29] .
With regard to thyroid tissues, growth-suppressive function of RKIP was demonstrated for undifferentiated thyroid carcinoma only [30] . In that study RKIP expression in UTC tissues was reduced as compared to papillary carcinoma and normal thyroid tissues. However that study did not include follicular thyroid carcinoma tissues and no relation between RKIP expression and metastases of thyroid carcinoma was shown. Our results clearly demonstrated the correlation between the reduction of RKIP and the development of lymph node and distant metastases. The diminished expression of RKIP in both differentiated and undifferentiated thyroid tissues may serve as a risk marker for thyroid carcinoma.
CONCLUSION
Since RKIP was independent of other clinical parameters, such as histological type, tumor differentiation grade and size, this study fully supports our conclusion that RKIP acts as a tumor suppressor gene that influences metastasis in thyroid carcinoma. 
